27 Sep 2019 | News

QUOTED. 27 September 2019. Jay Shah.

by

Abbott Laboratories gained FDA approval for its low-dose, recharge-free Proclaim XR neurostimulator. See what pain specialist Jay Shah, CEO and executive medical director of the SamWell Institute for Pain Management said about it here.

"The art of patient care is in finding the right therapy for the right patient, whether that be a technology that offers a rechargeable vs non-rechargeable option." – Jay Shah, CEO, SamWell Institute for Pain Management

• Find out more: <u>Abbott Wins FDA Approval For Low Dose Non-Rechargeable Spinal Cord</u> Stimulator

Click here for a free trial of Medtech Insight